Dual CCR9/CD1a CAR-T Cell Therapy for T-ALL
CCR9 expressed on >70% of T-ALL patients; dual targeting CCR9/CD1a achieves 86% patient coverage while preventing T cell aplasia.
Dual CCR9/CD1a CAR-T Cell Therapy for T-ALL Read More »
August 18, 2025
Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort
PTL is a rare extranodal malignancy accounting for <5% of thyroid cancer, with chemotherapy as cornerstone treatment, not surgery.
JNJ-5322 Trispecific Antibody Achieves 100% Response Rate in Relapsed/Refractory Multiple Myeloma Phase 1 Trial
Trispecific antibody JNJ-5322 achieves 100% response rate in R/R myeloma with improved oral toxicity vs current bispecifics.
FDA Expands Dostarlimab Approval in Endometrial Cancer
FDA extends dostarlimab approval for all endometrial cancer patients regardless of MMR/MSI status based on RUBY trial survival benefit.
FDA Expands Dostarlimab Approval in Endometrial Cancer Read More »
SOGUG-AUREA Trial: Split-Dose Cisplatin Plus Atezolizumab in Urothelial Carcinoma
Split-dose cisplatin + atezolizumab achieved 48.5% response rate in cisplatin-ineligible urothelial carcinoma patients with manageable toxicity.
SOGUG-AUREA Trial: Split-Dose Cisplatin Plus Atezolizumab in Urothelial Carcinoma Read More »
Palbociclib Resistance Biomarkers in Advanced Breast Cancer
ctDNA genotyping reveals ESR1, PIK3CA mutations and CCND1, FGFR1 amplifications predict worse outcomes with palbociclib in HR+/HER2- ABC.
Palbociclib Resistance Biomarkers in Advanced Breast Cancer Read More »
Plasma-Guided Adaptive Treatment for First-Line NSCLC Therapy
ctDNA kinetics guide treatment intensification in NSCLC, achieving 11.0-month median PFS with less platinum exposure than PD-L1 alone.
Plasma-Guided Adaptive Treatment for First-Line NSCLC Therapy Read More »
Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49
CRC screening in ages 45-49 jumped from 20.8% to 33.7% post-USPSTF guidelines, but gains limited to educated, insured populations.
Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49 Read More »